Electrogastrography associated with symptomatic changes after prokinetic drug treatment for functional dyspepsia by �엫�쁽泥� et al.
Hyun Chul Lim, Sang In Lee, Jiande DZ Chen, Hyojin Park
Electrogastrography associated with symptomatic changes 
after prokinetic drug treatment for functional dyspepsia
Hyun Chul Lim, Sang In Lee, Hyojin Park, Department of 
Internal Medicine, Yonsei University College of Medicine, Seoul 
120-752, South Korea
Jiande DZ Chen, Division of Gastroenterology, Department of 
Internal Medicine, University of Texas Medical Branch, Galves-
ton, TX 77555, United States
Author contributions: Park H designed the research; Lim HC, 
Lee SI and Chen JDZ wrote the paper.
Correspondence to: Hyojin Park, MD, Department of Inter-
nal Medicine, Yonsei University College of Medicine, Seoul 
120-752, South Korea. hjpark21@yuhs.ac
Telephone: +82-2-20193310  Fax: +82-2-34633882
Received: February 20, 2012  Revised: June 7, 2012
Accepted: June 28, 2012
Published online: November 7, 2012
Abstract
AIM: To evaluate the effect of prokinetic drugs on elec-
trogastrography (EGG) parameters according to symp-
tomatic changes in patients with functional dyspepsia 
(FD).
METHODS: Seventy-four patients with FD were pro-
spectively enrolled in this study between December 
2006 and December 2010. We surveyed the patients 
using a questionnaire on dyspeptic symptoms before 
and after an 8-wk course of prokinetic drug treatment. 
We also measured cutaneous pre-prandial and post-
prandial EGG recordings including percentage of gas-
tric waves (normogastria, bradygastria, tachygastria), 
dominant frequency (DF), dominant power (DP), domi-
nant frequency instability coefficient (DFIC), dominant 
power instability coefficient (DPIC), and the ratio of 
post-prandial to fasting in DP before and after the 8-wk 
course of prokinetic drug treatment. 
RESULTS: Fifty-two patients (70%) achieved symp-
tomatic improvement after prokinetic drug treatment. 
Patients who had normal gastric slow waves showed 
symptom improvement group after treatment. Post-
prandial DF showed a downward trend in the symptom 
improvement group, especially in the itopride group. 
Post-prandial DP was increased regardless of symp-
tom improvement, especially in the itopride group and 
mosapride group. Post-prandial DFIC and DPIC in the 
symptom improvement group were significantly in-
creased after the treatment. The EGG power ratio was 
increased after treatment in the symptom improvement 
group (0.50 ± 0.70 vs  0.93 ± 1.77, P  = 0.002), espe-
cially in the itopride and levosulpiride groups. 
CONCLUSION: Prokinetics could improve the symp-
toms of FD by regulating gastric myoelectrical activity, 
and EGG could be a useful tool in evaluating the effects 
of various prokinetics.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Electrogastrography (EGG) is a noninvasive technique 
for recording gastric myoelectrical activity using elec-
trodes on the abdominal wall overlying the stomach. 
EGG has been used as a diagnostic tool to determine 
the mechanism of  symptom generation in patients who 
have dyspeptic symptoms, including nausea, vomiting, 
post-prandial fullness, bloating, and early satiety, due to 
gastric motility disorders and abnormal gastric myoelec-
trical activity[1]. The EGG records the rhythms of  gastric 
slow waves, which provide information on the velocity 
and propagations of  gastric contractions. The previous 
studies showed the associations of  tachyarrhythmia with 
absent antral contractions, and bradyarrhythmia with 
strong or absent antral contractions[2]. Gastric dysryth-
mia including bradygastria and tachygastria is observed 
in 31%-69% of  patients with functional dyspepsia (FD), 
and several gastric rhythm abnormalities were described 
in patients with diabetic gastroparesis and motion sick-
ness[3-6]. EGG also records the gastric myoelectrical ac-
tivities which show the amplitude of  gastric contraction. 
The amplitude increases in the post-prandial state in 
healthy populations (90%-95%) and a lack of  an increase 
is believed to reflect decreased gastric motor activity[7].
Prokinetic drugs are used to treat FD by potentially 
enhancing gastrointestinal motility and accelerating gas-
tric emptying. Several prokinetic drugs, such as cisapride 
and domperidone, are known to correct dysrhythmias 
and symptoms in patients with gastroparesis and dyspep-
sia[8,9]. Recently, prokintics drugs, such as itopride hydro-
chloride, mosapride citrate, and levosulpiride, were used 
widely for treatment of  upper gastrointestinal motility 
disease, but the clinical utility of  changes in EGG param-
eters after treatment with these prokinetics in patients 
with FD symptoms has not been well established[10]. 
This prospective study was conducted to evaluate the 
effect of  itopride hydrochloride, mosapride citrate, and 
levosulpiride on EGG parameters according to symp-
tomatic changes in patients with FD. 
MATERIALS AND METHODS
Patients
This study was a prospective study approved by the 
Institutional Review Committee of  Yonsei University 
Health System and was conducted in compliance with 
the Declaration of  Helsinki. All patients were fully 
informed of  the purposes of  the study and written in-
formed consent was obtained from all patients prior to 
participation.
We reviewed patients who visited the Gangnam Sev-
erance Hospital, Yonsei University, South Korea for dys-
peptic symptoms between December 2006 and Decem-
ber 2010. Patients with symptoms meeting the Rome III 
criteria for FD underwent the following procedures[11]: 
an interview on medical history, physical examination, 
hematologic and chemical evaluations, upper esopha-
gogastro-duodenoscopy or an upper gastrointestinal 
series, before taking prokinetic drugs. Exclusion criteria 
included patients (1) who had organic or metabolic dis-
eases (i.e., diabetes mellitus, liver cirrhosis); (2) who had 
gastrointestinal diseases which had associated dyspeptic 
symptoms such as inflammatory bowel disease, cancer 
and ulcers; (3) who had a history of  abdominal surgery; 
and (4) who were taking drugs which could affect gas-
trointestinal motility, including other prokinetics, cholin-
ergic/anticholinergic agents, and antidepressive agents, 
for at least 4 wk prior to study start. 
Method
Protocol for drug administration: A prokinetic drug 
was administered after patients completed the question-
naires on FD and baseline EGG recordings were com-
pleted. The patients were assigned to one of  3 groups 
based on the type of  treatment drug: itopride hydrochlo-
ride (Ganaton®, Choogwae Pharma, South Korea) (n = 
24), mosapride citrate (Gasmotin®, Daewoong Pharma, 
South Korea) (n = 28), and levosulpiride (Levopride®, SK 
Chemical Life Science, South Korea) (n = 22). Itopride 
hydrochloride (50 mg tablet), mosapride citrate (5 mg tab-
let), and levosulpiride (25 mg tablet) were administered to 
patients in each group 3 times a day in the post-prandial 
state for 8 wk, and drugs which could affect gastrointesti-
nal function were not allowed to be used throughout the 
study.
Questionnaires for functional dyspepsia: Symptoms 
of  epigastric pain, epigastric burning, post-prandial 
fullness, early satiety, post-prandial bloating, and post-
prandial nausea or excessive belching were scored in ac-
cordance with the following scheme: 0 = none, 1 = mild 
(symptoms could be ignored if  the patient did not think 
about it), 2 = moderate (symptoms could not be ignored 
but did not influence daily activities), 3 = severe (symp-
toms influenced daily activities)[12]. For each patient, the 
total symptom severity score was the sum of  the 6 symp-
tom scores (minimum 0 to maximum 18). The frequency 
of  dyspeptic symptoms also described above was scored 
in accordance with the following scheme: 0 = none, 1 
= once or twice a month 2 = once or twice a week, 3 = 
more than 3 times a week. These scores were added to 
yield the total symptom frequency score (minimum 0 to 
maximum 18). The questionnaires were completed again 
after 8-wk treatment. 
Electrogastrography: EGG (Digitrapper EGG; Synet-
ics Medical Inc, Stockholm, Sweden) was used to record 
gastric myoelectrical activity with low and high cutoff  
frequencies of  1 and 10 cpm, respectively. After an 
overnight fast, EGG recordings were obtained in the 
morning for 30 min in the fasting state and for another 
30 min after a test meal at baseline before treatment. 
This procedure was repeated after 8-wk treatment. To 
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reduce the resistance between electrode and skin, hair 
was shaved and skin abraded with prepping paste (OMNI 
PREP®, D.O. Weaver & Co. United States) on the ab-
domen, and conductive cream (Signa Creme®, Parker 
Laboratories, United States) was applied to the skin. Two 
electrodes were placed on the abdomen, one midway be-
tween the xyphoid process and umbilicus, and the other 
5 cm to the left, just below the costal margin. A refer-
ence electrode was placed on the right side of  the abdo-
men. These electrodes were connected to a Digitrapper 
EGG recording devices. The patients were in a sitting 
position leaning 45° in a comfortable chair. The test 
meal was composed of  solid food (rice rolled up in dried 
seaweed with orange juice, 500 kcal). The EGG data 
were uploaded into a personal computer and analyzed 
by a software program (Polygram for Windows, version 
6.40, Synetics Medical Inc, Stockholm, Sweden). 
EGG recordings were analyzed to derive the fol-
lowing parameters: (1) percentage of  normal gastric 
waves (2.0-4.0 cpm), bradygastric waves (1.0-2.0 cpm), 
and tachygastric waves (4.0-10.0 cpm); (2) dominant 
frequency (DF); (3) dominant power (DP); (4) dominant 
frequency instability coefficient (DFIC, %); (5) dominant 
power instability coefficient (DPIC, %); and (6) the ratio 
of  post-prandial to fasting in DP. A percentage of  nor-
mal slow wave frequency of  more than 70% was defined 
as normal.
Statistical analysis
The patients were classified into 2 groups: a symptom 
improvement group if  symptom severity and frequency 
scores decreased after treatment with prokinetic drugs; 
and a symptom resistance group if  symptom sever-
ity and frequency scores increased or were unchanged 
after treatment. EGG parameters at baseline were com-
pared with post-treatment EGG parameters, according 
to symptomatic improvement and types of  prokinetic 
drugs used in this study.
Demographic data, questionnaire scores and param-
eters recorded in EGG were statistically analyzed by the 
paired Student t test and Fisher’s exact test using SPSS 
17.0. Data are expressed as the mean ± SE and a P-value 
< 0.05 was considered significant. 
RESULTS
This study included 74 patients (26 men, 48 women: 
median age 51.7 years, range: 19-70 years). After 8 wk 
of  prokinetic drug treatment, 52 patients (70%) showed 
symptomatic improvement, while 22 patients (30%) had 
no improvement or aggravated symptoms. There were 
no significant demographic differences between patients 
with improved symptoms and those without improve-
ment (Table 1). There were no significant differences in 
demographics, and symptom improvement rate among 
the itopride hydrochloride group, the mosapride citrate 
group, and the levosulpiride group (Table 2).
Symptom scores for functional dyspepsia
The mean symptom severity score for all patients was 
8.09 ± 0.43 at baseline vs 5.51 ± 0.46 post-treatment (P 
< 0.05). Symptom severity scores were significantly de-
creased in the symptom improvement group, while there 
were no significant changes in the symptom resistance 
group. Symptom severity scores were significantly de-
creased after all prokinetic drugs (Table 2). 
The mean symptom frequency score of  all patients 
was 9.27 ± 0.49 at baseline and 6.81 ± 0.54 after treat-
ment (P < 0.05). Symptom frequency scores were signifi-
cantly decreased in the symptom improvement group, 
while there were no significant changes in the symptom 
resistance group. Symptom severity scores were de-
creased after all prokinetic drugs, but significant differ-
ences were shown only in the itopride hydrochloride 
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Table 1  Patient demographics and pattern of dysrhythmia according to symptom improvement  
Total patients (n  = 74) Symptom improvement (n  = 52) Symptom resistance (n  = 22)
Male:female (n) 26:48 18:34 8:14
Age (range), yr 51.7 (19-70) 53.5 (27-70) 47.6 (19-70)
Height 165.2 ± 12.4 166.3 ± 11.6 164.9 ± 10.1
Weight 61.3 ± 9.7 62.3 ± 9.1   58.8 ± 10.2
Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
Symptom severity score 8.09 ± 0.43 5.51 ± 0.46a 8.90 ± 0.46 4.52 ± 0.47a 6.18 ± 0.85 7.86 ± 0.92
Symptom frequency score 9.27 ± 0.49 6.81 ± 0.54a 9.96 ± 0.54 5.79 ± 0.60a 7.64 ± 1.01 9.23 ± 0.97
Gastric dysrhythmia (pre-prandial)
   Bradygastria 16 (21.6) 11 (14.9)   9 (17.3)   7 (13.5)     6 (27.3)    4 (18.2)
   Normogastria 33 (44.6) 52 (70.3)a 26 (50.0)  37 (71.2)a     9 (40.9) 15 (68.2)
   Tachygastria 25 (33.8) 11 (14.9)a 17 (32.7)    8 (15.4)a     7 (31.8)   3 (13.6)
Gastric dysrhythmia (post-prandial)
   Bradygastria 17 (23.0) 10 (13.5) 10 (19.2)   6 (11.5)     4 (18.2)   4 (18.2)
   Normogastria 33 (44.6) 45 (60.8) 26 (50.0)  37 (71.2)a 11 (50) 13 (59.1)
   Tachygastria 24 (32.4) 19 (25.7) 16 (30.8) 14 (26.9)     7 (31.8)   5 (22.7)
aP < 0.05 vs pre-treatment group. Data are presented by mean ± SD or n (%). 
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ndial DF showed no significant changes regardless of  
symptom improvement or type of  prokinetic drug (Figure 
2). Post-prandial DF was decreased after treatment in 
the symptom improvement group and especially in the 
itopride treatment group. Pre-prandial DP showed no 
significant changes regardless of  symptom improvement 
or prokinetic drug after treatment. Post-prandial DP was 
increased regardless of  symptom improvement especially 
in the itopride group (19.34 ± 6.08 at baseline vs 42.49 
± 6.13 after treatment, P = 0.010) and mosapride group 
(24.04 ± 6.47 at baseline vs 56.24 ± 11.83 after treatment, 
P = 0.020). 
Dominant frequency instability coefficient and 
dominant power instability coefficient: Pre-prandial 
DFIC and DPIC after treatment were not changed 
regardless of  symptom improvement and type of  pro-
kinetic drug (Figure 2). Post-prandial DFIC and DPIC 
were significantly increased after treatment (74.29% ± 
24.45% vs 82.69% ± 27.05%, P = 0.035) in the symptom 
improvement group, but there was no significant differ-
ences between the prokinetics. 
Power ratio: After treatment, the EGG power ratio was 
increased in the symptom improvement group (0.64 ± 
0.07 vs 1.23 ± 0.16, P = 0.002), especially in the levosul-
piride treatment group (Figure 3).
DISCUSSION
FD is a common clinical syndrome characterized by 
pain or discomfort in the upper abdomen without any 
identifiable structural or biochemical abnormality. The 
pathophysiology of  FD involves various mechanisms, 
including delayed gastric emptying, impaired accommo-
dation in the proximal stomach, and increase duodenal 
group (Table 2). 
Parameters of EGG recording
Patients who had gastric dysrhythmia: After proki-
netic treatment, the number of  patients who had normal 
gastric slow waves was increased in the symptom im-
provement group and in the itopride treatment group. In 
particular, the number of  patients who had tachygastria 
were decreased in the symptom improvement group and 
in the itopride treatment group (Tables 1 and 2).
Percentage of  gastric slow waves: The pre-prandial 
percentage of  gastric slow waves was 64.99% ± 2.93% 
for normal, 14.01% ± 1.93% for bradygastria, and 
18.73% ± 2.24% for tachygastria at pre-treatment (Fig-
ure 1A). At the end of  the 8-wk treatment, the percent-
age of  pre-prandial gastric slow waves was 68.47% ± 
2.54% for normal, 16.12% ± 2.94% for bradygastria, 
and 15.09% ± 1.71% for tachygastria. Dysrythmia did 
not show significant changes regardless of  symptom 
improvement. The itopride treatment group showed 
significant decreases in pre-prandial tachygastria, but 
there were no significant changes in the mosapride and 
levosulpiride treatment groups. The percentage of  post-
prandial gastric slow waves was 63.08% ± 2.25% for 
normal, 16.52% ± 2.22% for bradygastria and 20.09% 
± 2.05% for tachygastria at pre-treatment. At the end 
of  prokinetic treatment, the percentage of  post-prandial 
gastric slow waves was 63.87% ± 2.25% for normal, 
16.52% ± 1.92% for bradygastria, and 20.09% ± 19.48% 
for tachygastria (Figure 1B). There were no significant 
changes regardless of  symptom improvement, nor were 
there any significant changes among the itopride, mo-
sapride, and levosulpiride treatment groups.
Dominant frequency and dominant power: Pre-pra-
Table 2  Demographic and treatment success of patients and pattern of dysrhythmia according to prokinetic drugs 
Itopide (n  = 24) Mosapride (n  = 28) Levosulpiride (n  = 22)
Male:female (n) 5:19 10:18 11:11
Age (range), yr 49.8 (30-64) 49.6 (19-70) 56.6 (39-70)
Height 166.1 ± 10.1 163.0 ± 11.0 167.1 ± 13.2
Weight 60.8 ± 7.7   62.7 ± 11.5   61.3 ± 10.5
Symptom improvement 18 (75) 17 (61) 17 (77)
Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
Symptom severity score 7.96 ± 0.84 5.00 ± 0.86a 7.61 ± 0.64  5.46 ± 0.79a 8.86 ± 0.76  6.14 ± 0.76a
Symptom frequency score 9.21 ± 0.92 6.08 ± 0.99a 8.86 ± 0.78 6.86 ± 0.89 9.86 ± 0.83 7.55 ± 0.96
Gastric dysrhythmia (pre-prandial) 
   Bradygastria   5 (20.8)   4 (16.7)    6 (21.4)   4 (14.3)   4 (18.2)   3 (13.6)
   Normogastria   8 (33.3)  17 (70.8)a  15 (53.6) 18 (64.3) 12 (54.5) 15 (68.2)
   Tachygastria 11 (45.8)    3 (12.6)a 7 (25)   6 (21.4)   6 (27.3)   4 (18.2)
Gastric dysrhythmia (post-prandial)
   Bradygastria   5 (20.8)   3 (12.5)    6 (21.4)   6 (21.4)   3 (13.6) 1 (4.5)
   Normogastria 11 (45.8) 14 (58.3)  12 (42.9) 16 (57.1) 14 (63.6) 15 (68.2)
   Tachygastria   8 (33.3)   7 (29.2)  10 (35.7)   6 (21.4)   5 (22.7)   6 (27.3)
aP < 0.05 vs pre-treatment group. Data are presented by mean ± SD or n (%). 
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Figure 1  Proportion of gastric slow waves on electrogastrography. A: Pre-prandial; B: Post-prandial. aP < 0.05 vs pre-treatment. 
sensitivity to lipid or acid, and pathologic factors include 
genetic susceptibility, Helicobacter pylori (H. pylori) infec-
tion, and psychological factors[13]. There has been no sin-
gle available therapy for FD due to the heterogeneity of  
the symptoms and various mechanisms and pathologic 
factors. Accordingly, a wide variety of  treatment meth-
ods have been used for FD such as dietary and lifestyle 
modification, H. pylori eradication, antacids, mucosal 
protectants, prokinetics, and psychological and comple-
mentary therapy[13].
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Figure 2  Changes in dominant frequency and dominant power, dominant frequency instability coefficient and dominant power instability coefficient after 
prokinetic treatment. A: Dominant frequency (DF) in pre-prandial electrogastrography (EGG); B: DF in post-prandial EGG; C: Dominant power (DP) in pre-prandial 
EGG; D: DP in post-prandial EGG; E: Dominant frequency instability coefficient (DFIC) in pre-prandial EGG; F: DFIC in post-prandial EGG; G: Dominant power insta-
bility coefficient (DPIC) in pre-prandial EGG; H: DPIC in post-prandial EGG. aP < 0.05 vs pre-treatment.
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Abnormal gastric motility such as delayed gastric 
emptying or uncoordinated antral contraction is com-
mon in functional dyspepsia[14,15]. Gastrointestinal motor 
dysfunctions can be assessed by gastric emptying scan 
and/or manometry, and gastric myoelectrical abnormali-
ties can be detected by noninvasive cutaneous EGG. 
EGG as a diagnostic technique has been frequently used 
for the detection of  gastric dysrhythmia in patients with 
nausea, vomiting and other dyspeptic symptoms. Several 
previous studies have shown a positive correlation be-
tween abnormal EGG and delayed gastric emptying[16-18]. 
The most common abnormal EGG finding is dys-
rhythmia, low EGG power ratio and high instability 
coefficient[19-22]. The percentage of  patients who had gas-
tric dysrhythmia (percent of  normal slow waves < 70%) 
were 55.4% at pre-prandial and post-prandial periods 
in our study. This data was similar to previous studies 
which reported dysrhythmias in 31%-69% of  func-
tional dyspepsia cases[4]. However, we did not find any 
significant difference in the percentage of  gastric slow 
waves between the symptom improvement group and 
the symptom resistance group after treatment and there 
were no correlations between gastric dysrhythmia and 
symptom severity or symptom frequency either. This 
could be because FD symptoms are caused by different 
abnormalities, for example, impaired gastric accommo-
dation (vagally and nitrergically mediated mechanisms) 
may cause symptoms but this has little to do with gastric 
slow waves[23]. 
Prokinetics such as cisapride (5-HT4 agonist/weak 
5-HT3 antagonist) and domperidone (D2 antagonist) 
have been shown to improve gastric dysrhythmia in 
patients with diabetic gastroparesis, whereas low dose 
erythromycin was reported to have no effects on dys-
rhythmia[24-27]. Few studies showed that mosapride 
improved the gastric dysrhythmia and power ratio. In 
our study, itopride, mosapride and levopride showed 
improvements in gastric dysrhythmia in the pre-prandial 
state, but significant differences were shown only with 
itopride[28,29]. 
The DF reflects the regularity of  gastric slow waves 
and the DP reflects the amplitude of  gastric slow waves. 
However, the relationship of  DF and DP with func-
tional dyspepsia was not clear[30]. Our data showed a 
decrease in post-prandial DF in the symptom improve-
ment group, and post-prandial DP was high regardless 
of  symptom improvement. Itopride significantly de-
creased post-prandial DF, and both itopride and mo-
sapride increased post-prandial DP. According to this 
study, prokinetics might improve the symptoms of  FD 
by improvement in dysrhythmic gastric movement which 
is represented by decreased DF, and by activating gastric 
movement which is represented by increased DP. 
DPIC increases during antral contractions, and 
DFIC increases during pregnancy and in patients with 
gastroesophageal reflux disease. Previous studies showed 
that pediatric patients who have dyspeptic symptoms 
reported a high instability coefficient, however, there 
was not enough data showing the relationship between 
the DPIC/DFIC and clinical symptoms in FD patients 
clearly[31-33]. Our data showed increased DPIC/DFIC in 
the symptom improvement group after prokinetic drug 
treatment[34]. Increased DPIC/DFIC might be due to 
the increased variability of  changes in gastric movement 
activated by prokinetics.
The EGG power ratio increases after an appropriate 
test meal in normal subjects, and decreases in gastropa-
resis and FD patients[1]. The EGG power ratio increased 
in responders after prokinetic treatment with itopride 
and levosulpiride, but not with mosapride in our study. 
The EGG power ratio is believed to be associated with 
gastric contractility; the increase in the EGG power ratio 
observed in this study reflected an increase in gastric 
contractions. This data is in agreement with previous 
studies in that prokinetics, especially levosulpiride, in-
creased gastric contractions or gastric emptying[35].
In summary, dysrhythmia was recorded about half  of  
the time in FD patients, and prokinetic treatment suc-
cessfully improved symptoms. The symptom improve-
ment group showed decreased post-prandial DF and 
increased post-prandial DP, DFIC/DPIC and power 
ratio after treatment with prokinetics. Itopride improved 
gastric dysrhythmia, decreased post-prandial DF, and 
increased post-prandial DP; mosapride increased post-
prandial DP and levosulpiride increased the EGG power 
ratio. 
The mechanism of  prokinetics on gastric electrical 
activity could be (1) to stabilize the gastric slow waves 
which is represented by an improvement in gastric dys-
rhythmia and a decrease in post-prandial DF; and (2) to 
increase gastric motility which is represented by an in-
crease in post-prandial DP and in the EGG power ratio 
by activating gastric movements which is represented by 
increased DPIC/DFIC.
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Figure 3  Power ratio before and after the 8-wk course of treatment. aP < 
0.05 vs pre-treatment.
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In conclusion, the findings of  this study suggest 
that prokinetics could improve the symptoms of  FD by 
regulating gastric myoelectrical activity, and the EGG 
could be a useful tool to evaluate the effects of  various 
prokinetics.
COMMENTS
Background
Electrogastrography (EGG) abnormalities are frequently observed in patients 
with functional dyspepsia (FD). However, changes in EGG parameters after 
treatment with prokinetics according to symptom improvement have not been 
well investigated. 
Research frontiers
Prokinetic drugs are used in functional dyspepsia to enhance gastrointestinal 
motility and correct dysrhythmias in FD patients. In this study, the authors ob-
served that prokinetics could improve the symptoms of FD by regulating gastric 
myoelectrical activity. 
Innovations and breakthroughs
Prokinetics successfully improved symptoms of FD, but the improvement did 
not seem to be correlated with any of the EGG parameters. Instead, there were 
some unique changes in EGG parameters according to the prokinetic drug. 
This study suggests that different prokinetics may have different mechanisms of 
action in regulating gastric myoelectrical activity, and the EGG could be a useful 
tool in evaluating the effects of various prokinetics.
Applications
There was controversy in the significance of EGG as diagnostic tool in FD due 
to the lack of data and standardized methodology. By understanding the chang-
es in EGG parameters, this study might indicate a future strategy for EGG in 
evaluating the improvement in FD after prokinetic drug treatment. This study is 
an important basis for future experiments using EGG in pharmacology.
Terminology
EGG represents gastric myoelectrical activity. Dysrhythmia (bradygastria, 
tachygastria) reflect uncoordinated antral contraction, and the power ratio re-
flects gastric contractions. Dominant frequency reflects the regularity of gastric 
slow waves and dominant power reflects the amplitude of gastric slow waves. 
Dominant power instability coefficient increases during antral contractions and, 
dominant frequency instability coefficient increases during pregnancy. 
Peer review
The authors tried to clarify the relation of EGG and FD symptoms and found 
the symptom improvement group after prokinetics therapy showed decreased 
post-prandial dominant frequency and increased dominant frequency instability 
coefficient/dominant power instability coefficient and increased power ratio. 
REFERENCES
1 Parkman HP, Hasler WL, Barnett JL, Eaker EY. Electrogas-
trography: a document prepared by the gastric section of the 
American Motility Society Clinical GI Motility Testing Task 
Force. Neurogastroenterol Motil 2003; 15: 89-102 
2 Abell TL, Malagelada JR. Glucagon-evoked gastric dys-
rhythmias in humans shown by an improved electrogastro-
graphic technique. Gastroenterology 1985; 88: 1932-1940 
3 Brzana RJ, Koch KL, Bingaman S. Gastric myoelectrical 
activity in patients with gastric outlet obstruction and idio-
pathic gastroparesis. Am J Gastroenterol 1998; 93: 1803-1809 
4 Chen J, McCallum RW. Gastric slow wave abnormalities 
in patients with gastroparesis. Am J Gastroenterol 1992; 87: 
477-482
5 Koch KL. Electrogastrography: physiological basis and clini-
cal application in diabetic gastropathy. Diabetes Technol Ther 
2001; 3: 51-62
6 Stern RM, Koch KL, Stewart WR, Lindblad IM. Spectral 
analysis of tachygastria recorded during motion sickness. 
Gastroenterology 1987; 92: 92-97
7 Parkman HP, Harris AD, Miller MA, Fisher RS. Influence of 
age, gender, and menstrual cycle on the normal electrogas-
trogram. Am J Gastroenterol 1996; 91: 127-133 
8 Saad RJ, Chey WD. Review article: current and emerging 
therapies for functional dyspepsia. Aliment Pharmacol Ther 
2006; 24: 475-492 
9 Jung IS, Kim JH, Lee HY, Park H, Lee SI. Endoscopic evalu-
ation of gastric emptying and effect of mosapride citrate on 
gastric emptying. Yonsei Med J 2010; 51: 33-38 
10 Pohle T, Domschke W. Gastric function measurements in 
drug development. Br J Clin Pharmacol 2003; 56: 156-164 
11 Drossman DA. The functional gastrointestinal disorders and 
the Rome III process. Gastroenterology 2006; 130: 1377-1390 
12 Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating 
scale for gastrointestinal symptoms in patients with irritable 
bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 
33: 129-134 
13 El-Serag HB, Talley NJ. Systemic review: the prevalence and 
clinical course of functional dyspepsia. Aliment Pharmacol 
Ther 2004; 19: 643-654 
14 Tack J, Bisschops R, Sarnelli G. Pathophysiology and treat-
ment of functional dyspepsia. Gastroenterology 2004; 127: 
1239-1255 
15 Camilleri M, Brown ML, Malagelada JR. Relationship be-
tween impaired gastric emptying and abnormal gastrointes-
tinal motility. Gastroenterology 1986; 91: 94-99 
16 Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel 
syndrome and dyspepsia in the general population: overlap 
and lack of stability over time. Gastroenterology 1995; 109: 
671-680 
17 Chen JD, Lin Z, Pan J, McCallum RW. Abnormal gastric 
myoelectrical activity and delayed gastric emptying in pa-
tients with symptoms suggestive of gastroparesis. Dig Dis 
Sci 1996; 41: 1538-1545 
18 Parkman HP, Miller MA, Trate D, Knight LC, Urbain JL, 
Maurer AH, Fisher RS. Electrogastrography and gastric 
emptying scintigraphy are complementary for assessment of 
dyspepsia. J Clin Gastroenterol 1997; 24: 214-219
19 Levanon D, Zhang M, Chen JD. Efficiency and efficacy of 
the electrogastrogram. Dig Dis Sci 1998; 43: 1023-1030
20 Lin X, Chen JZ. Abnormal gastric slow waves in patients 
with functional dyspepsia assessed by multichannel elec-
trogastrography. Am J Physiol Gastrointest Liver Physiol 2001; 
280: G1370-G1375 
21 Koch KL, Hong SP, Xu L. Reproducibility of gastric myo-
electrical activity and the water load test in patients with 
dysmotility-like dyspepsia symptoms and in control sub-
jects. J Clin Gastroenterol 2000; 31: 125-129 
22 Lu CL, Chen CY, Chang FY, Kang LJ, Lee SD, Wu HC, Kuo 
TS. Impaired Post-prandial gastric myoelectrical activity in 
Chinese patients with nonulcer dyspepsia. Dig Dis Sci 2001; 
46: 242-249 
23 Kindt S, Tack J. Impaired gastric accommodation and its 
role in dyspepsia. Gut 2006; 55: 1685-1691 
24 Chang CS, Lien HC, Yeh HZ, Poon SK, Tung CF, Chen GH. 
Effect of cisapride on gastric dysrhythmia and emptying of 
indigestible solids in type-II diabetic patients. Scand J Gastro-
enterol 1998; 33: 600-604
25 Orr WC, Zhang M, McClanahan J, Sloan S, Chen JD. Gastric 
myoelectric activity in older adults treated with cisapride for 
gastro-oesophageal reflux disease. Aliment Pharmacol Ther 
2000; 14: 337-343 
26 Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric empty-
ing and gastric myoelectrical activity in patients with diabet-
ic gastroparesis: effect of long-term domperidone treatment. 
Am J Gastroenterol 1989; 84: 1069-1075 
27 Chen JD, Lin ZY, Edmunds MC, McCallum RW. Effects of 
octreotide and erythromycin on gastric myoelectrical and 
motor activities in patients with gastroparesis. Dig Dis Sci 
1998; 43: 80-89 
Lim HC et al . Electrogastrography after prokinetic drug treatment
 COMMENTS
5956 November 7, 2012|Volume 18|Issue 41|WJG|www.wjgnet.com
28 Kamiya T, Adachi H, Hirako M, Shikano M, Matsuhisa E, 
Wada T, Ogasawara N, Nojiri S, Kataoka H, Sasaki M, Ohara 
H, Joh T. Impaired gastric motility and its relationship to re-
flux symptoms in patients with nonerosive gastroesophageal 
reflux disease. J Gastroenterol 2009; 44: 183-189
29 Endo J, Nomura M, Morishita S, Uemura N, Inoue S, Kishi S, 
Kawaguchi R, Iga A, Ito S, Nakaya Y. Influence of mosapride 
citrate on gastric motility and autonomic nervous function: 
evaluation by spectral analyses of heart rate and blood pres-
sure variabilities, and by electrogastrography. J Gastroenterol 
2002; 37: 888-895
30 Stevens JE, Russo A, Maddox AF, Rayner CK, Phillips L, 
Talley NJ, Giguère M, Horowitz M, Jones KL. Effect of ito-
pride on gastric emptying in longstanding diabetes mellitus. 
Neurogastroenterol Motil 2008; 20: 456-463 
31 Chen JD, Richards RD, McCallum RW. Identification of gas-
tric contractions from the cutaneous electrogastrogram. Am J 
Gastroenterol 1994; 89: 79-85 
32 Riezzo G, Pezzolla F, Darconza G, Giorgio I. Gastric myo-
electrical activity in the first trimester of pregnancy: a cuta-
neous electrogastrographic study. Am J Gastroenterol 1992; 
87: 702-707
33 Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De 
Roo M, Muls E, Bouillon R. Improvement of gastric empty-
ing in diabetic gastroparesis by erythromycin. Preliminary 
studies. N Engl J Med 1990; 322: 1028-1031
34 Chen JD, Lin X, Zhang M, Torres-Pinedo RB, Orr WC. Gas-
tric myoelectrical activity in healthy children and children 
with functional dyspepsia. Dig Dis Sci 1998; 43: 2384-2391 
35 Levanon D, Zhang M, Orr WC, Chen JD. Effects of meal vol-
ume and composition on gastric myoelectrical activity. Am J 
Physiol 1998; 274: G430-G434 
S- Editor  Gou SX    L- Editor  Cant MR    E- Editor  Zhang DN
Lim HC et al . Electrogastrography after prokinetic drug treatment
